@article{ref1,
title="Persistently high circulating tissue inhibitor of matrix metalloproteinase-1 levels in non-survivor brain trauma injury patients",
journal="Journal of critical care",
year="2019",
author="Lorente, Leonardo and Martín, María M. and Ramos, Luis and Argueso, Mónica and Cáceres, Juan J. and Solé-Violán, Jordi and Jiménez, Alejandro and Borreguero-León, Juan M. and González-Rivero, Agustín F. and Orbe, Josune and Rodriguez, Jose A. and Páramo, José A.",
volume="51",
number="",
pages="117-121",
abstract="PURPOSE: Previously, higher circulating levels of matrix metalloproteinase (MMP)-9 and tissue inhibitor matrix metalloproteinases (TIMP)-1 were reported in the first hours after TBI in blood samples from patients with poor prognosis. Thus, the objectives of this study were to determine whether MMP-9 and TIMP-1 levels during the first week of a severe TBI could be used as biomarker predictive of mortality. <br><br>METHODS: We included patients with severe TBI (defined as Glasgow Coma Scale lower than 9), and with Injury Severity Score in non-cranial aspects lower than 9. We determined serum concentrations of MMP-9 and TIMP-1 at days 1, 4 and 8 of TBI. <br><br>RESULTS: TIMP-1 concentrations at days 1 (p < .001), 4 (p = .001), and 8 (p = .01) of TBI were higher in non-surviving (n = 34) than in surviving (n = 90) patients. ROC curve analyses showed an area under curve of TIMP-1 concentrations at days 1, 4, and 8 of TBI to predict 30-day mortality of 78% (p < .001), 76% (p < .001) and 71% (p = .02) respectively. <br><br>CONCLUSIONS: The most relevant new findings of our study were that TIMP-1 levels during the first week of a severe TBI were higher in non-surviving than in surviving patients and that could be used as biomarker predictive of mortality.<br><br>Copyright © 2019 Elsevier Inc. All rights reserved.<p /> <p>Language: en</p>",
language="en",
issn="0883-9441",
doi="10.1016/j.jcrc.2019.02.014",
url="http://dx.doi.org/10.1016/j.jcrc.2019.02.014"
}